Falls and Functional Impairments in Breast Cancer Patients with Chemotherapy-Induced Peripheral Neuropathy
Falls and Functional Impairments in Breast Cancer Patients with Chemotherapy-Induced Peripheral Neuropathy
复制标题
DOI：
10.4103/apjon.apjon_7_19
复制
发表时间：
2019-07-01
影响因子：
1.8
通讯作者：
Doorenbos, Ardith Z.
中科院分区：
文献类型：
--
作者：
Komatsu, Hiroko;Yagasaki, Kaori;Doorenbos, Ardith Z.
目的：我们调查了乳腺癌化疗诱导的周围神经病变（CIPN）患者的福尔斯和功能障碍的发生率。此外，我们还研究了紫杉烷诱导的周围神经病变是否与患者的福尔斯跌倒和功能障碍有关。研究方法：我们进行了一项横断面研究，包括88例接受紫杉烷为基础的化疗并被认为有周围神经病变症状（不良事件通用术语标准等级>= 1）的乳腺癌患者。患者完成了癌症治疗功能评估-妇科肿瘤组-神经毒性神经病变问卷，并描述了从紫杉烷化疗开始到调查时的福尔斯。功能障碍的定义是使用弱势老年人量表的日常生活活动部分。资料以描述性统计及逻辑回归分析。结果：在参与者中，40.9%的人经历过福尔斯，38.4%的人报告功能障碍。大多数福尔斯都发生在平地上。在11.4%的参与者中观察到由于福尔斯跌倒导致的骨折。Logistic回归分析显示，CIPN与报告的福尔斯发生率无显著相关性。然而，它与功能障碍显著相关（比值比，6.415; 95%置信区间：1.271-32.379; P = 0.024）。结论：CIPN与功能障碍有关，但与福尔斯的发生率无关。在开始抗癌治疗前，应告知患者CIPN是功能损害的风险因素。
Objective: We investigated the incidence of falls and functional impairments in breast cancer patients with chemotherapy-induced peripheral neuropathy (CIPN). Additionally, we examined whether taxane-induced peripheral neuropathy was associated with the patients' falls and functional impairments. Methods: We conducted a cross-sectional study including 88 patients with breast cancer who received taxane-based chemotherapy and were recognized as having peripheral neuropathy symptoms (Common Terminology Criteria for Adverse Events Grade >= 1). Patients completed the Functional Assessment of Cancer Therapy-Gynecologic Oncology Group-Neurotoxicity questionnaire for neuropathy and described falls from the onset of the taxane-based chemotherapy to the time of the survey. Functional impairments were defined using the Activities of Daily Living subsection of the Vulnerable Elder's Scale. Data were analyzed using descriptive statistics and logistic regression. Results: Of the participants, 40.9% experienced falls and 38.4% reported functional impairments. Most falls occurred on flat ground. Bone fracture due to falls was observed in 11.4% of the participants. Logistic regression revealed that CIPN was not significantly associated with the reported incidence of falls. However, it was significantly associated with functional impairments (odds ratio, 6.415; 95% confidence interval: 1.271-32.379; P = 0.024). Conclusions: CIPN was associated with functional impairments, but not with the incidence of falls. Patients should be informed prior to the onset of anticancer therapy that CIPN is a risk factor for functional impairments.